Bibliographic Application
Navigating Global Regulations with Precision while Uncovering Drug Discovery through Expert Bibliographic Application
We unlock your regulatory approval through scientific literature & ensure your pathway to efficiency & compliance
Ensuring international regulatory norms is crucial in the pharmaceutical sector, and bibliographic applications are vital in providing reliable and current information to support regulatory procedures.
- Overview
Article 10a of Directive 2001/83/EC and Section 22(3)(1) of the German Medicines Act require submission of data for Modules 1 through 3. If a medicinal product’s active ingredients have been used for at least ten years in the Union with recognized efficacy and safety, pre-clinical and clinical trials can be replaced with specific references to published scientific literature. A comprehensive scientific bibliography covering all preclinical and clinical features is necessary for this evidence. For this purpose, this form of application is termed as bibliographical application.
The type of literature sources and content are crucial for a bibliographic application, as submitted work must be published by a reliable source and freely available in public domain. The data from own preclinical and clinical research may not be considered in the bibliographical application. Assessment reports, like EPAR for EU marketing authorizations or summary reports from competent authorities cannot be considered for transparency reasons. To establish the effectiveness and safety of a medical product, applicants must include both positive and negative literature data in their evidence and explain any missing information in a contentious manner.
How do we assist you with our Bibliographic Application Services
People Also Ask (FAQs)
A bibliographic application is a regulatory submission pathway where a pharmaceutical company seeks drug approval based on published scientific literature and existing clinical data rather than conducting new clinical trials. This approach is commonly used when sufficient scientific evidence about the safety and efficacy of the active substance is already available in peer-reviewed publications.
A bibliographic regulatory submission is typically used when the active pharmaceutical ingredient (API) is well established in medical practice and supported by extensive published clinical studies. In such cases, regulatory authorities may accept literature-based evidence to demonstrate the drug’s safety, efficacy, and therapeutic value. Zenovel supports this process by conducting thorough literature reviews, compiling scientific evidence, and preparing well-structured dossiers aligned with regulatory expectations to ensure successful submission outcomes.
A bibliographic application dossier includes peer-reviewed scientific articles, clinical study publications, safety reports, meta-analyses, and regulatory references that support the safety and efficacy of the drug. These documents are carefully compiled and evaluated to meet regulatory requirements for drug approval based on literature evidence.
Zenovel provides expert support for preparing bibliographic regulatory submissions, including systematic literature review, scientific data compilation, regulatory documentation, and dossier preparation. Their regulatory specialists ensure that published evidence is properly structured and aligned with international regulatory guidelines, improving the chances of successful approval.
A bibliographic application can significantly reduce development time and cost because it relies on existing published clinical and scientific evidence rather than new clinical trials. This pathway allows pharmaceutical companies to pursue regulatory approval more efficiently, especially for well-established active substances with extensive scientific documentation.
Blogs and news
Our Latest Article
Introduction to Generic Inhalation Product Development Inhalation products pose significant challenges in generic drug development due to the complexity of formulations and device technology, making bioequivalence more difficult to establish compared to conventional oral dosage forms. Examples include Albuterol MDIs (metered dose inhalers), DPIs Dry Powder Inhalers, and nebulized therapies,
India is a significant player in the global pharmaceuticals sector, characterized by a diverse population and cost-effective infrastructure. However, its potential in clinical research is hindered by complex regulatory challenges that delay innovations and deter investment, affecting the timely market introduction of life-saving drugs. This blog discusses the major obstacles
The FDA issued 466 Form 483s to drug organizations in FY 2022, more than double the previous year, highlighting significant quality failures in the pharmaceutical sector. For startups and scale-ups seeking market approval, the excitement of innovation often conflicts with the strict requirements of current good manufacturing practices (cGMP). Although
Introduction Liposomal Amphotericin-B is a critical antifungal medication that requires careful attention during Bioequivalence (BE) studies. These studies aim to demonstrate the similarity of a generic liposomal Amphotericin B formulation to the reference drug in terms of pharmacokinetics. Zenovel, with its extensive experience in monitoring Amphotericin B studies, can play
In the pharmaceutical and biotechnology industries, obtaining regulatory approval is essential prior to introducing new drugs or biologics to the market. A pivotal aspect of this approval process is the FDA Pre-Approval Inspection (PAI), which involves a comprehensive assessment of manufacturing facilities, processes, and data integrity to ensure adherence to
Risk Based Monitoring (RBM) is a more efficient alternative to traditional clinical trials, focusing on high-risk areas through data-driven insights. It ensures patient safety, data integrity, and regulatory compliance while reducing costs and timelines. However, the success of RBM depends on the competency of monitors, who identify risks, analyze data,
